RxDoctor Payments Data

Devin Kehl, MD

Cardiovascular Disease · Santa Monica, CANPI 1316253024

Payments from drug & device makers

$6,945in general payments, 2019–2025

Across 179 payments — averaging $38.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$3K
  • Abbott$1K
  • Novartis$711
  • E.r. Squibb & Sons, L.L.C.$366
  • Amgen$338
  • Boehringer Ingelheim$225
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$3,49950%
  • Food & beverage$3,44550%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,945 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$632,291
Medicare patients
1,438
Services billed
21,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$274,208
Repatha SureclickEvolocumab240$261,469
JardianceEmpagliflozin127$167,852
EntrestoSacubitril/Valsartan108$122,570
FarxigaDapagliflozin Propanediol59$59,731
Praluent PenAlirocumab62$45,411
XareltoRivaroxaban35$37,193
MounjaroTirzepatide16$16,224
Rosuvastatin Calcium557$9,946
Ezetimibe166$6,229
Atorvastatin Calcium466$5,764
Metoprolol Succinate292$5,000
Amiodarone Hcl32$3,331
Valsartan111$3,276
Olmesartan Medoxomil99$2,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$274,208242 claims
Boehringer IngelheimJardiance$225$167,852127 claims
NovartisEntresto$711$122,570108 claims
AstraZenecaFarxiga$65$59,73159 claims
Johnson & JohnsonXarelto$113$37,19335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →